Excellergy Inc. emerged from stealth with a $70 million Series A to advance effector cell response inhibitors (ECRIs), a new class designed to remove IgE from effector cells without triggering mast cell activation. Investors led by Samsara Biocapital funded the company to push its lead candidate toward first‑in‑human studies early next year. The company cites structural IgE biology from Stanford and the University of Bern as the scientific foundation. Excellergy’s pitch is to deliver faster, more complete disease control across allergic indications than current anti‑IgE therapies; the financing will support IND‑enabling studies and initial clinical development.